NasdaqCM:CORTPharmaceuticals
Corcept Lawsuits Put Relacorilant Setback And Investor Risk In Focus
Multiple shareholder class action lawsuits have been filed against Corcept Therapeutics (NasdaqCM:CORT) after the company disclosed that the FDA issued a Complete Response Letter for relacorilant.
Plaintiffs allege Corcept and certain executives misrepresented FDA communications and the likelihood of approval for relacorilant prior to the New Drug Application decision.
The lawsuits claim that longstanding regulatory concerns about the clinical evidence for relacorilant were not adequately...